non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH)
Conditions
Interventions
Group 1: Control group:
BMI >30 and/or DM II without antiplatelet therapy
Baseline:
Evaluation of NAFLD/NASH with liver MRI, Fibroscan, hematologic and clinical parameters
After 6 months:
Evaluation
Sponsors
Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with an age from 18-80 years with symptomatic cardiovascular disease and a high-risk profile including diabetes mellitus type II and/or obesity with BMI =30
Exclusion criteria
Exclusion criteria: History of viral hepatitis Patients with alcoholic steatohepatitis (ASH) Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of level of steatosis and fibrosis in patients with NAFLD (non-alcoholic fatty liver disease)/NASH (non-alcoholic steatohepatitis) by administration of antiplatelet therapy Diagnosis and evaluation of course of NAFLD/NASH are obtained by liver MRI, Fibroscan, hematologic and clinical parameters at baseline and after 6months of follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of liver volume and liver parameters (GOT/GPT) in patients with NAFLD/NASH by administration of antiplatelet therapy Diagnosis and evaluation of course of liver volume and GOT/GPT are obtained by liver MRI and blood drawing at baseline and after 6months of follow-up | — |
Countries
Germany
Contacts
Public ContactDominik Rath
Universitätsklinikum Tübingen
Outcome results
None listed